Centre for Bioscience, Faculty of Science & Engineering, Manchester Metropolitan University, Manchester, UK.
Institute of Clinical Chemistry, University and University Hospital Zurich, University Heart Center, Zurich, Switzerland.
Cardiovasc Res. 2021 Jan 1;117(1):29-42. doi: 10.1093/cvr/cvaa085.
Endothelial cells (ECs) are sentinels of cardiovascular health. Their function is reduced by the presence of cardiovascular risk factors, and is regained once pathological stimuli are removed. In this European Society for Cardiology Position Paper, we describe endothelial dysfunction as a spectrum of phenotypic states and advocate further studies to determine the role of EC subtypes in cardiovascular disease. We conclude that there is no single ideal method for measurement of endothelial function. Techniques to measure coronary epicardial and micro-vascular function are well established but they are invasive, time-consuming, and expensive. Flow-mediated dilatation (FMD) of the brachial arteries provides a non-invasive alternative but is technically challenging and requires extensive training and standardization. We, therefore, propose that a consensus methodology for FMD is universally adopted to minimize technical variation between studies, and that reference FMD values are established for different populations of healthy individuals and patient groups. Newer techniques to measure endothelial function that are relatively easy to perform, such as finger plethysmography and the retinal flicker test, have the potential for increased clinical use provided a consensus is achieved on the measurement protocol used. We recommend further clinical studies to establish reference values for these techniques and to assess their ability to improve cardiovascular risk stratification. We advocate future studies to determine whether integration of endothelial function measurements with patient-specific epigenetic data and other biomarkers can enhance the stratification of patients for differential diagnosis, disease progression, and responses to therapy.
内皮细胞(ECs)是心血管健康的哨兵。它们的功能会因心血管危险因素的存在而降低,一旦病理刺激物被清除,其功能就会恢复。在这份欧洲心脏病学会立场文件中,我们将内皮功能障碍描述为表型状态的连续谱,并主张进一步研究以确定 EC 亚型在心血管疾病中的作用。我们得出的结论是,没有一种单一的理想方法可以测量内皮功能。测量冠状动脉心外膜和微血管功能的技术已经成熟,但它们具有侵袭性、耗时且昂贵。肱动脉血流介导的扩张(FMD)提供了一种非侵入性的替代方法,但技术上具有挑战性,需要广泛的培训和标准化。因此,我们建议普遍采用 FMD 的共识方法,以最大限度地减少研究之间的技术差异,并为不同健康人群和患者群体建立参考 FMD 值。用于测量内皮功能的较新技术相对易于操作,例如指容积描记法和视网膜闪烁试验,如果在使用的测量方案上达成共识,它们有可能增加临床应用。我们建议进行进一步的临床研究,以确定这些技术的参考值,并评估其改善心血管风险分层的能力。我们主张未来的研究确定是否可以将内皮功能测量与患者特定的表观遗传数据和其他生物标志物相结合,以增强患者的分层,用于鉴别诊断、疾病进展和对治疗的反应。